These findings highlight the ongoing need for baseline CD4 count measurement to identify a large number of patients with AHD among ART-naïve patients, in order to provide differentiated models of care for this group of patients [5], guide prophylaxis against opportunistic infections (severe bacterial infections, TB and cryptococcal disease), and reduce mortality [41, 45–48]. This evidence concerns the gene CD4 and Opportunistic infection.